Capital Flow Monitor · Sponsors · CIK 1816722
Ansa Biotechnologies, Inc.
1198 65TH STREET #250, EMERYVILLE, CA, 94608 · 9256908100
Biotechnology · Corporation· inc. DELAWARE true
Fit score
—
Offering
$56.9M
Sold
$46.4M
% sold
81.6%
Investors
41
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2025-12-10 | D/A ·current | 506(b) | $56.9M | $46.4M | 81.6% | 41 | EDGAR ↗ |
| 2025-10-02 | D | 506(b) | $55.5M | $45.2M | 81.5% | 39 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Jason T. Gammack — Executive Officer / Director, Emeryville, CA
- Daniel Lin-Arlow — Executive Officer / Director, Emeryville, CA
-
Yanniv Dorone — Director, Emeryville, CA
1 other raise
- ARZEDA Corp. $4.5M of $25.0M · 18.0%
- Matthew McManus — Director, Emeryville, CA
-
Chenny Zhang — Director, Emeryville, CA
2 other raises
- Virchow Medical, Inc. $4.1M of $4.1M · 100.0%
- SYNTIS BIO, INC. $25.0M of $26.5M · 94.3%
- Sebastian Palluk — Executive Officer, Emeryville, CA
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.